For July....without BB buying ...Any rational for up move is appreciated...we will not see earning till next month..so what is your idea...I am long this stock for past 3+ yrs but slowing down on accumulation size...except selling naked in money PUTS..
Genomic Health (NASDAQ: GHDX) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a research note issued on Wednesday. The firm currently has a $43.00 price target on the stock. Zacks‘ analyst wrote, “Genomic Health reported a strong first quarter with both revenue and earnings sailing past the Zacks Consensus Estimates. The company recorded a robust increase in Oncotype DX tests delivered. Besides, the company is making progress on its colon cancer test based on the recent launch of MMR testing and some favorable reimbursement decisions. Moreover, Genomic is focusing on the international market that has recorded significant growth during the quarter. In spite of involving additional investment, we are encouraged by the company’s focus on sequencing. Given the long term potential of the company, we upgrade the stock to Outperform’. “ Separately, analysts at Canaccord Genuity reiterated a “hold” rating on shares of Genomic Health in a research note to investors on Thursday, May 3rd. Genomic Health traded up 2.59% on Wednesday, hitting $36.04. Genomic Health has a 52-week low of $19.00 and a 52-week high of $36.15. The company has a market cap of $1.083 billion and a price-to-earnings ratio of 123.70. Genomic Health last posted its quarterly earnings results on Wednesday, May 2nd. The company reported $0.02 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.02) by $0.04. The company’s quarterly revenue was up 17.4% on a year-over-year basis. Analysts expect that Genomic Health will post $0.01 EPS next quarter. Genomic Health, Inc. (Genomic Health) is a molecular diagnostics company focused on the development and global commercialization of genomic-based clinical laboratory services , which analyzes the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.
Breaking 52 week high on such low low micro volume does not have much of meaning...you should know that ...you claim to be pro-trader...GHDX does not have typical technical characteristic due to schewed ownership and low trade volume
(1) Expanding acceptance of product in Europe. (2) Continued development of colon etc additional products. (3) Potential for acquisition at any time (4) Remarkable price appreciation in otherwise difficult market (5) Lack of sellers, institutions and public in general agreement that this is a superb buy and hold candidate. Traders with 100% success ratios are like unicorns, they don't exist. Trading this stock means you buy back at higher prices, or short into a small float security which is a way to turn your hair white.